Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26536604 | 0.81 | GPR119 (0.37) | GPR119POLBMEN1KMT2ABCHE | |
| SCHEMBL5172212 | 0.81 | GPR119 (0.38) | GPR119POLBMEN1KMT2ABCHE | |
| SCHEMBL14825921 | 0.80 | CYP3A4 (0.33) | POLBKMT2A | |
| SCHEMBL1097122 | 0.79 | GPR119 (0.38) | GPR119POLBMEN1KMT2ABCHE | |
| SCHEMBL6172899 | 0.79 | GPR119 (0.38) | GPR119POLBMEN1KMT2ABCHE | |
| SCHEMBL23376785 | 0.79 | GPR119 (0.38) | GPR119POLBMEN1KMT2ABCHE | |
| SCHEMBL24915163 | 0.79 | GPR119 (0.38) | GPR119POLBMEN1KMT2ABCHE | |
| SCHEMBL2800325 | 0.79 | GPR119 (0.35) | GPR119POLBMEN1KMT2ABCHE | |
| SCHEMBL5849847 | 0.78 | GPR119 (0.37) | GPR119POLBMEN1KMT2ABCHE | |
| SCHEMBL2471937 | 0.78 | GPR119 (0.37) | GPR119POLBMEN1KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | disclosed |
| WO-2024259328-A1 | INHIBITORS OF RIPK2 AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20230391778-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2018052773-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| EP-3160957-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-20170101409-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-04-13 | — | — | US | disclosed |
| WO-2016073652-A1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | UNITHER VIROLOGY, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015197567-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| EP-2552893-B1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-20130096119-A1 | Isoquinolin-3-Ylurea Derivatives | BUR DANIEL (CH) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101409-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN-2-ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | GPR119 340/4885POLB 891/4885MEN1 2090/4885 |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | GPR119 2397/4885POLB 629/4885MEN1 1213/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | GPR119 2397/4885POLB 629/4885MEN1 1213/4885 |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | TNNI3, MUSK, MYLK2 | GPR119 1171/4885POLB 4235/4885MEN1 4665/4885 |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | GPR119 2397/4885POLB 629/4885MEN1 1213/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | GPR119 2397/4885POLB 629/4885MEN1 1213/4885 |
| US-20130096119-A1 | Isoquinolin-3-Ylurea Derivatives | CLIC1, IRF3, KCNH3 | GPR119 702/4885POLB 2784/4885MEN1 1786/4885 |
| US-20230391778-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | GPR119 340/4885POLB 891/4885MEN1 2090/4885 |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | GPR119 2397/4885POLB 629/4885MEN1 1213/4885 |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | GPR119 770/4885POLB 2813/4885MEN1 2993/4885 |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | GPR119 340/4885POLB 891/4885MEN1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.